acut
cough
major
symptom
viral
respiratori
tract
infect
caus
excess
morbid
human
popul
across
world
wide
varieti
virus
play
role
develop
cough
acut
infect
manifest
similar
clinic
pictur
across
differ
age
group
despit
larg
diseas
burden
surprisingli
littl
known
mechan
acut
cough
follow
viral
infect
vitro
vivo
experi
show
increas
product
neuropeptid
leukotrien
mediat
cough
viral
infect
along
alter
express
neural
receptor
increas
airway
mucu
product
also
like
play
signific
role
work
review
articl
follow
recent
develop
mous
model
rhinoviru
infect
establish
experiment
model
rhinoviru
challeng
human
subject
asthma
copd
field
expand
translat
vitro
research
clinic
studi
hope
eventu
clinic
practic
develop
clearer
understand
mechan
underli
viru
induc
cough
may
lead
specif
effect
therapi
acut
cough
major
symptom
viral
respiratori
tract
infect
caus
excess
morbid
human
popul
across
world
wide
varieti
virus
play
role
develop
cough
acut
infect
manifest
similar
clinic
pictur
across
differ
age
group
despit
larg
diseas
burden
surprisingli
littl
known
mechan
acut
cough
follow
viral
infect
vitro
vivo
experi
show
increas
product
neuropeptid
leukotrien
mediat
cough
viral
infect
along
alter
express
neural
receptor
increas
airway
mucu
product
also
like
play
signific
role
work
review
articl
follow
recent
develop
mous
model
rhinoviru
infect
establish
experiment
model
rhinoviru
challeng
human
subject
asthma
copd
field
expand
translat
vitro
research
clinic
studi
hope
eventu
clinic
practic
develop
clearer
understand
mechan
underli
viru
induc
cough
may
lead
specif
effect
therapi
elsevi
ltd
right
reserv
upper
respiratori
tract
infect
urti
common
ill
patient
seek
medic
attent
cough
frequent
symptom
present
gener
practition
caus
excess
morbid
human
popul
across
world
urti
result
estim
million
consult
unit
state
one
year
alon
financi
cost
top
us
billion
half
indirect
cost
million
school
work
day
lost
absente
year
effect
antivir
therapi
urti
yet
american
spend
us
billion
year
counter
cold
remedi
although
gener
self
limit
symptom
cough
often
persist
week
follow
viral
infect
addit
subgroup
patient
develop
chronic
cough
symptom
prolong
last
month
year
acut
coryza
common
cold
primarili
caus
virus
picornaviru
coronaviru
famili
mani
aetiolog
agent
identifi
howev
includ
human
metapneumoviru
hmpv
parainfluenza
influenza
b
respiratori
syncyti
virus
rsv
clinic
identif
viru
type
minim
signific
produc
similar
symptom
nasopharyng
cough
futur
develop
specif
antivir
therapi
howev
necessit
accur
viral
identif
present
perform
research
set
cough
healthi
subject
due
respiratori
viral
infect
common
symptom
childhood
fall
frequenc
adult
life
prospect
studi
follow
children
first
year
life
aim
defin
aetiolog
respiratori
tract
infect
weekli
symptom
record
demonstr
infant
develop
urti
amongst
viru
identifi
predominantli
rhinovirus
coronavirus
infant
acut
viral
infect
develop
cough
demonstr
signific
symptom
childhood
acut
cough
healthi
adult
almost
exclus
associ
respiratori
tract
infect
gender
relat
differ
acut
chronic
cough
identifi
amongst
women
incid
cough
higher
present
medic
care
provid
lower
cough
threshold
provoc
test
confirm
object
cough
monitor
found
acut
chronic
cough
use
sensit
molecular
techniqu
possibl
detect
virus
major
asthma
exacerb
children
exacerb
associ
viru
exacerb
adult
rhinovirus
consist
frequent
viru
type
detect
found
around
twothird
case
viru
identifi
exact
mechan
viru
infect
trigger
exacerb
airway
diseas
still
unclear
like
repres
constel
host
immun
respons
specif
viral
action
infect
respiratori
epithelium
lead
cascad
proinflammatori
cytokin
recruit
activ
immun
cell
airway
mucu
hypersecret
follow
viru
infect
like
key
factor
airway
obstruct
cough
aetiolog
airway
diseas
exacerb
postul
asthmat
patient
suscept
viru
infect
longitudin
cohort
studi
found
asthmat
increas
risk
develop
rhinoviru
infect
develop
longer
last
sever
lower
respiratori
tract
symptom
infect
healthi
control
reduc
antivir
activ
asthmat
subject
may
account
recent
studi
found
peripher
blood
monocyt
asthmat
expos
rhinoviru
defici
product
interferongamma
ifng
compar
normal
subject
follow
experiment
infect
defici
induct
cytokin
demonstr
augment
induct
cytokin
asthmat
subject
addit
model
demonstr
defici
level
ifnl
lambda
primari
bronchial
epitheli
cell
alveolar
macrophag
correl
sever
exacerb
viru
load
aetiolog
role
virus
exacerb
copd
becom
increasingli
clear
infect
identifi
major
exacerb
one
studi
exacerb
associ
infect
sever
result
greater
drop
lung
function
prolong
hospitalis
compar
noninfect
exacerb
virus
detect
exacerb
like
repres
underestim
subject
report
symptom
cold
prior
exacerb
detect
rate
vari
depend
method
sampl
collect
analysi
well
exacerb
sever
cough
common
symptom
copd
significantli
increas
period
exacerb
infect
incid
viral
respiratori
tract
infect
vari
throughout
year
healthi
individu
frequent
develop
urti
earli
autumn
associ
increas
incid
cough
present
medic
servic
epidemiolog
studi
demonstr
strike
impact
season
factor
exacerb
frequenc
asthma
copd
asthma
exacerb
children
peak
around
mid
late
septemb
strongli
correl
return
school
peak
copd
exacerb
follow
decemb
associ
christma
holiday
season
seen
everi
northern
hemispher
countri
studi
trend
reflect
complex
combin
mani
caus
factor
primari
caus
exacerb
respiratori
viru
infect
particularli
rhinoviru
peak
asthma
exacerb
correl
highest
incid
rhinoviru
infect
commun
reason
delay
copd
exacerb
clear
remark
studi
directli
investig
mechan
viru
induc
cough
provid
insight
investig
airway
hyperrespons
ahr
rather
cough
outcom
measur
convers
studi
specif
investig
cough
studi
experiment
viru
infect
cough
physiolog
respons
airway
irrit
import
defenc
mechan
respiratori
tract
inhibit
normal
host
respons
viral
infect
may
necessarili
desir
therefor
howev
transmiss
viru
particl
individu
enabl
cough
like
virus
evolv
mechan
produc
enhanc
cough
product
caus
cough
complex
multifactori
mani
divers
aetiolog
agent
infect
identifi
sever
pathway
mediat
via
vagu
nerv
activ
central
cough
gener
brainstem
stimul
neurotransmitt
respiratori
tract
cough
gener
activ
laryng
oesophag
tracheobronchi
receptor
addit
voluntari
control
viru
infect
one
exampl
cough
may
stimul
via
pathway
direct
indirect
action
viru
infect
airway
epithelium
lead
inflamm
cytokin
releas
host
immun
system
activ
virus
influenza
may
highli
pathogen
caus
excess
epitheli
cell
necrosi
inflamm
howev
even
rhinovirus
milder
pathogen
less
direct
cellular
necrosi
lead
mark
symptomat
host
respons
viru
infect
epitheli
cell
releas
wide
rang
inflammatori
cytokin
includ
tnfa
groa
rant
gmcsf
eotaxin
addit
express
growth
factor
adhes
molecul
immun
relat
molecul
upregul
viru
infect
recent
longitudin
studi
exacerb
sever
asthmat
identifi
increas
ifng
produc
tcell
exacerb
defici
regulatori
cell
found
baselin
also
exagger
exacerb
studi
offer
new
insight
pathophysiolog
asthma
exacerb
although
virus
investig
studi
futur
work
explor
role
cellular
chang
viru
infect
lung
lead
increas
airway
neurotransmitt
particularli
tachykinin
substanc
p
varieti
differ
mechan
tachykinin
neuroexcitatori
molecul
act
potent
vasodil
caus
contract
airway
smooth
muscl
secret
airway
mucu
substanc
p
found
elev
bronchoalveolar
lavag
bal
fluid
rsv
infect
mice
implic
lymphocyt
respons
studi
rsv
infect
mice
found
elev
substanc
p
level
also
fall
airway
protect
compound
calcitonin
generel
peptid
cgrp
cgrp
neuropeptid
vasodil
effect
constitut
found
airway
defici
airway
found
inflam
hyperrespons
central
role
substanc
p
viru
induc
airway
dysfunct
confirm
shown
select
block
substanc
p
receptor
receptor
sendid
abolish
ahr
viru
infect
respiratori
tract
caus
tachykinin
releas
ad
nerv
fibr
guinea
pig
also
decreas
activ
neutral
endopeptidas
ne
import
enzym
involv
degrad
airway
tachykinin
rat
studi
use
rsv
demonstr
significantli
higher
level
substanc
p
lung
tissu
follow
infect
addit
stimul
capsaicin
increas
substanc
p
releas
infect
lung
compar
control
work
guinea
pig
confirm
high
potenc
substanc
p
cough
gener
effect
ne
limit
inactiv
cough
gener
tachykinin
ne
limit
cough
activ
exogen
inhibitor
ne
abl
increas
sensit
substanc
p
increas
cough
frequenc
lower
dose
respons
curv
capsaicin
induc
cough
guinea
pig
addit
total
increas
tachykinin
level
lung
express
receptor
increas
amplifi
viru
induc
neurostimulatori
signal
effect
shown
young
rat
depend
nerv
growth
factor
ngf
neutralis
antibodi
ngf
abolish
effect
exogen
addit
ngf
upregul
receptor
level
addit
level
ngf
fell
increas
age
may
indic
mechan
exagger
viru
induc
airway
diseas
infant
addit
increas
neurotransmitt
receptor
follow
viru
infect
shown
qualit
chang
affer
nerv
occur
experiment
infect
guinea
pig
sendai
viru
shown
label
affer
neuron
trachea
increas
size
follow
viru
infect
resolv
convalesc
tachykinin
synthesis
neuron
cell
bodi
diamet
increas
acut
infect
suggest
viru
infect
lead
chang
vagal
affer
innerv
guinea
pig
airway
small
diamet
nociceptivelik
neuron
larg
diamet
nonnocicept
neuron
express
tachykinin
despit
signific
impact
viru
infect
appear
cholinerg
pathway
research
specif
cough
undertaken
area
surrog
marker
bronchoconstrict
ahr
use
instead
viru
infect
appear
activ
bronchoconstrict
vagu
nerv
acetylcholin
level
increas
inhibitori
effect
muscarin
receptor
lost
viru
infect
shown
potenti
cell
anim
infect
parainfluenza
viru
releas
acetylcholin
noninfect
cell
receptor
activ
disrupt
ifngamma
g
exposur
suggest
potenti
mechan
viru
induc
cough
possibl
increas
sensit
affer
nerv
muscarin
receptor
also
shown
play
central
role
airway
vascular
leakag
bronchoconstrict
mucu
secret
model
gastrooesophag
reflux
cough
may
promin
featur
stimul
acid
activ
muscarin
receptor
effect
block
specif
antagonist
studi
specif
investig
cough
mechan
cholinerg
activ
leukotrien
lt
potent
mediat
bronchoconstrict
vascular
dilat
mucu
product
ahr
use
surrog
marker
cough
produc
arachidon
acid
activ
protein
flap
lead
product
cysteinyllt
specif
particularli
eosinophil
basophil
potent
mediat
bronchial
asthma
aspirin
induc
asthma
inhibit
follow
administr
nonsteroid
antiinflammatori
drug
produc
excess
lt
consequ
worsen
ahr
bronchoconstrict
attempt
specif
inhibit
activ
compound
led
new
therapeut
agent
montelukast
zafirlukast
studi
nonatop
normal
subject
use
experiment
rhinoviru
infect
bronchoscopi
perform
week
prior
infect
repeat
day
viru
inocul
identifi
increas
airway
inflamm
increas
macrophag
mast
cell
bronchial
biopsi
acut
infect
biopsi
sampl
fold
increas
cell
count
stain
posit
flap
respect
addit
stain
induc
enzym
respons
prostaglandin
pg
synthesi
significantli
increas
studi
demonstr
increas
capac
product
lt
pg
cold
symptom
assess
studi
use
jackson
cold
score
system
includ
cough
symptom
indic
score
correl
stain
cell
count
flap
support
link
symptom
viru
induc
lt
lt
level
also
shown
increas
rsv
infect
possibl
aetiolog
role
bronchiol
randomis
control
trial
lt
antagonist
montelukast
found
improv
lung
symptom
score
rsv
bronchiol
studi
specif
investig
pathway
cough
would
interest
mucu
hyper
secret
well
recognis
diseas
airway
particularli
copd
mucu
product
form
part
definit
chronic
bronchiti
product
also
stimul
viru
infect
mucu
like
signific
induc
cough
least
part
direct
airway
irrit
vitro
investig
promin
airway
mucin
identifi
key
signal
pathway
molecul
specif
signal
gene
promot
activ
transcript
factor
follow
stimul
model
inflammatori
stimulu
pma
subsequ
vitro
rhinoviru
infect
human
tracheal
cell
submucos
gland
demonstr
upregul
mrna
mucin
produc
gene
level
mrna
protein
total
mucin
concentr
also
elev
effect
attenu
follow
addit
nfkb
mitogen
activ
protein
map
kinas
inhibitor
suggest
signal
molecul
import
mucu
hypersecret
follow
viru
infect
suggest
inhibitor
potenti
therapeut
target
vivo
rhinoviru
infect
shown
induc
level
bal
vitro
studi
demonstr
occur
result
new
mrna
synthesi
signal
pathway
characteris
detail
transcript
factor
nfkb
shown
involv
follow
rv
infect
nfkb
activ
matrix
metalloproteinas
mediat
releas
transform
growth
factor
tgf
occur
turn
activ
epiderm
growth
factor
receptor
lead
activ
protein
kinas
signal
mapk
mek
erk
final
signal
gene
transcript
increas
henc
protein
level
elev
ca
hewson
et
al
unpublish
result
investig
mechan
viru
induc
cough
suffer
lack
small
anim
model
viru
induc
cough
particularli
rhinoviru
common
viru
infect
human
repeatedli
indentifi
frequent
viru
acut
exacerb
airway
diseas
major
group
rhinovirus
serotyp
bind
human
intercellular
adhes
cellular
receptor
howev
unabl
bind
mous
recent
gener
mousehuman
chimera
enabl
mous
model
rhinoviru
infect
creat
addit
model
includ
sensitis
subsequ
rechalleng
ovalbumen
creat
featur
atopi
combin
rhinoviru
infect
provid
model
asthma
exacerb
absenc
cough
mice
ahr
would
use
surrog
cough
howev
guinea
pig
abl
cough
may
prove
use
model
futur
sendai
rsv
infect
establish
guinea
pig
rv
infect
present
attempt
avail
small
anim
model
prove
invalu
develop
therapi
cough
human
challeng
studi
rhinoviru
perform
healthi
subject
asthma
copd
experiment
infect
human
allow
investig
complet
physiolog
system
detail
characteris
subject
baselin
prior
infect
regular
interv
throughout
infect
convalesc
provid
opportun
detail
investig
cough
symptom
throughout
full
timelin
rhinoviru
infect
potenti
investig
vivo
mechan
viru
induc
cough
healthi
subject
well
airway
diseas
cough
frequent
symptom
copd
yet
use
surprisingli
infrequ
monitor
diseas
assess
treatment
respons
experiment
challeng
studi
rv
infect
perform
patient
mild
moder
copd
age
smoke
match
nonobstruct
control
model
shown
safe
valid
model
studi
copd
exacerb
subject
kept
symptom
diari
card
throughout
studi
reveal
signific
increas
cough
score
group
acut
viral
infect
compar
baselin
score
new
model
provid
excit
opportun
investig
mechan
cough
copd
futur
studi
nonsmok
control
arm
await
interest
order
permit
separ
effect
smoke
copd
report
cough
patient
highli
subject
mani
factor
mood
health
belief
coexist
symptom
may
bia
report
therefor
object
assess
cough
monitor
develop
sound
cough
record
digit
number
individu
cough
time
spent
cough
calcul
investig
system
valid
correl
video
record
shown
respons
symptom
chang
follow
use
cystic
fibrosi
patient
object
monitor
cough
stabl
copd
perform
shown
cough
frequent
day
correl
lung
function
test
mani
differ
system
measur
cough
develop
research
commerci
purpos
addit
system
detail
least
two
group
uk
develop
cough
monitor
system
moder
correl
subject
score
observ
opportun
combin
object
monitor
experiment
rhinoviru
infect
would
provid
uniqu
opportun
studi
cough
control
welldefin
popul
without
airway
diseas
copd
asthma
exacerb
could
studi
would
provid
data
durat
sever
cough
follow
viral
infect
would
facilit
investig
mechan
cough
also
provid
opportun
test
potenti
therapi
effect
antituss
medic
avail
viru
mediat
cough
often
use
clinic
strategi
tradit
concentr
symptom
reduct
advanc
antivir
therapi
like
result
direct
attempt
modul
viru
replic
recent
placebo
control
studi
nonsmok
urti
found
tiotropium
long
act
anticholinerg
effect
reduc
cough
reflex
sensit
follow
stimul
capsaicin
associ
chang
lung
function
author
suggest
antituss
effect
tiotropium
may
mechan
bronchodil
doubl
blind
placebo
control
studi
nasal
ipratropium
bromid
report
decreas
sneez
rhinorrhea
howev
cough
investig
specif
studi
reduct
cough
also
achiev
doubl
blind
administr
pseudoephedrin
brompheniramin
first
gener
antihistamin
howev
effect
seen
newer
nonsed
antihistamin
use
may
less
anticholinerg
activ
side
effect
like
limit
use
sedat
drug
routin
practic
particularli
children
nsaid
naproxen
decreas
cough
associ
symptom
doubl
blind
placebo
control
studi
use
experiment
rv
challeng
conclud
prostaglandin
among
inflammatori
mediat
play
role
rv
induc
cold
symptom
includ
cough
specif
antivir
therapi
studi
use
like
limit
wide
varieti
virus
respons
urti
difficulti
prescrib
appropri
absenc
rapid
accur
diagnost
test
antivir
ruprintrivir
use
experiment
rv
cold
reduc
mean
daili
symptom
score
given
hour
infect
prophylact
use
reduc
viral
load
reduc
frequenc
cold
review
rv
chemotherapi
conclud
effect
drug
avail
studi
trial
use
clinic
difficult
almost
immedi
diagnosi
treatment
viru
infect
requir
ribavirin
effect
antivir
rsv
larger
clinic
studi
lack
power
demonstr
benefit
bronchiol
although
conflict
evid
literatur
specif
shown
reduc
cough
symptom
central
act
cough
suppressor
specif
viru
induc
cough
gener
avoid
side
effect
profil
doubl
blind
placebo
control
studi
use
object
subject
cough
monitor
found
littl
support
convent
antituss
placebo
urti
associ
cough
altern
therapi
may
develop
futur
need
minim
side
effect
rapid
onset
action
use
urti
control
cough
acut
cough
repres
highli
signific
burden
without
lung
diseas
major
episod
cough
due
acut
respiratori
viru
infect
present
therapi
directli
target
suboptim
present
understand
viru
infect
like
gener
cough
select
alter
neural
signal
neurokinin
level
specif
receptor
may
increas
addit
reduct
degrad
enzym
cholinerg
pathway
appear
show
promis
target
futur
therapi
drug
act
favour
side
effect
profil
short
long
act
compound
shown
benefici
effect
leukotrien
also
may
play
mechanist
role
promot
cough
excess
product
mucu
healthi
diseas
lung
probabl
play
signific
role
viru
induc
cough
area
includ
potenti
promis
therapeut
target
inhibit
prostaglandin
synthesi
shown
benefici
symptom
reduct
understand
mechan
acut
viru
infect
gener
cough
poor
research
requir
recent
establish
human
anim
experiment
model
allow
adapt
specif
object
studi
cough
hope
lead
better
understand
underli
mechan
addit
would
provid
opportun
test
new
therapeut
compound
becom
avail
